The triple negative BC subtype (TNBC) is characterized by metastatic progression, poor patient prognosis, and is identified by the absence of bio-molecules that form the basis for targeted therapies for the other BC subtypes, namely estrogen receptor, progesterone receptor, and Her2 amplification.15 Thus, there are currently no FDA approved targeted therapies for TNBC. The gene discussed is ESR1; the disease is breast cancer.